JP2008520669A - エリスロポエチン抵抗性を治療する方法 - Google Patents

エリスロポエチン抵抗性を治療する方法 Download PDF

Info

Publication number
JP2008520669A
JP2008520669A JP2007543135A JP2007543135A JP2008520669A JP 2008520669 A JP2008520669 A JP 2008520669A JP 2007543135 A JP2007543135 A JP 2007543135A JP 2007543135 A JP2007543135 A JP 2007543135A JP 2008520669 A JP2008520669 A JP 2008520669A
Authority
JP
Japan
Prior art keywords
human
iron
erythropoietin
iron chelator
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007543135A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008520669A5 (https=
Inventor
ブイ． シャー，スディア
Original Assignee
シバ バイオメディカル，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シバ バイオメディカル，エルエルシー filed Critical シバ バイオメディカル，エルエルシー
Publication of JP2008520669A publication Critical patent/JP2008520669A/ja
Publication of JP2008520669A5 publication Critical patent/JP2008520669A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2007543135A 2004-11-19 2005-11-10 エリスロポエチン抵抗性を治療する方法 Pending JP2008520669A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62960604P 2004-11-19 2004-11-19
PCT/US2005/040898 WO2006055412A1 (en) 2004-11-19 2005-11-10 Methods of treating erythropoietin-resistance

Publications (2)

Publication Number Publication Date
JP2008520669A true JP2008520669A (ja) 2008-06-19
JP2008520669A5 JP2008520669A5 (https=) 2008-12-25

Family

ID=35809986

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007543135A Pending JP2008520669A (ja) 2004-11-19 2005-11-10 エリスロポエチン抵抗性を治療する方法

Country Status (6)

Country Link
US (1) US20060128805A1 (https=)
EP (1) EP1819334A1 (https=)
JP (1) JP2008520669A (https=)
AU (1) AU2005306772A1 (https=)
CA (1) CA2587558A1 (https=)
WO (1) WO2006055412A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010032489A1 (ja) 2008-09-22 2010-03-25 国立大学法人旭川医科大学 鉄キレート剤及びその製造方法、並びに鉄イオンの定量・捕捉方法
WO2012096183A1 (ja) 2011-01-14 2012-07-19 株式会社ダステック 高分子鉄キレート剤

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083966A (en) 1998-08-31 2000-07-04 University Of Florida Thiazoline acid derivatives
WO2005034949A1 (en) 2003-09-09 2005-04-21 University Of Florida Desferrithiocin derivatives and their use as iron chelators
BRPI0610644B8 (pt) 2005-04-04 2021-05-25 Univ Florida composto e composição farmacêutica que compreende tal composto e um veículo ou diluente farmaceuticamente aceitável.
CA2607953A1 (en) 2005-05-09 2006-11-16 Tap Pharmaceutical Products, Inc. Methods for treating nephrolithiasis
BRPI0715123A2 (pt) * 2006-08-04 2013-06-04 Novartis Ag tratamento de disfunÇço endàcrina usando quelantes de ferro
EP2101761A4 (en) * 2006-11-13 2010-01-27 Takeda Pharmaceuticals North A METHODS FOR PRESERVING RENAL FUNCTION USING XANTHINE OXYDOREDUCTASE INHIBITORS
US20080132465A1 (en) * 2006-12-05 2008-06-05 Vincent Windisch Apparatus and method for isolating iron components from serum
US20100137346A1 (en) * 2006-12-12 2010-06-03 University Of Florida Research Foundation, Inc. Desferrithiocin analogue actinide decorporation agents
JP5439193B2 (ja) 2007-03-15 2014-03-12 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． デスフェリチオシンポリエーテル類似体
WO2010045589A2 (en) * 2008-10-17 2010-04-22 The General Hospital Corporation Optimizing erythropoietin therapy
KR101735125B1 (ko) * 2008-11-12 2017-05-15 리젠메드 (케이만) 엘티디. 분리된 신장 세포 및 이의 용도
WO2011143292A1 (en) * 2010-05-11 2011-11-17 Ohio University Biomarkers for detecting erythropoietin use in human subjects
AU2011299153B2 (en) 2010-09-10 2014-10-30 Takeda Pharmaceuticals U.S.A., Inc. Methods for concomitant treatment of theophylline and febuxostat
SG193494A1 (en) 2011-03-21 2013-10-30 Vivolux Ab Treatment of solid tumours
JP6539046B2 (ja) 2011-12-16 2019-07-03 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． ４’−デスフェリチオシン類似体の使用
WO2014046589A1 (en) 2012-09-21 2014-03-27 Vivolux Ab Means and method for treating solid tumours
CA2930966A1 (en) 2013-11-22 2015-05-28 University Of Florida Research Foundation, Inc. Desferrithiocin analogs and uses thereof
JP6725515B2 (ja) 2015-01-09 2020-07-22 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ 小分子を用いた鉄欠乏生物における生理機能の回復
EP3288557A4 (en) 2015-04-27 2018-11-07 University of Florida Research Foundation, Inc. Metabolically programmed metal chelators and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62223130A (ja) * 1985-11-25 1987-10-01 ザ　ホスピタル　フオ−　シツク　チルドレン 複合治療剤，その製造方法及び製剤又は製剤パツク

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62223130A (ja) * 1985-11-25 1987-10-01 ザ　ホスピタル　フオ−　シツク　チルドレン 複合治療剤，その製造方法及び製剤又は製剤パツク

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN5007021135; ＫＯＵＲＹ　Ｍ　Ｊ: ＴＨＥ　ＮＥＷ　ＥＮＧＬＡＤ　ＪＯＵＲＮＡＬ　ＯＦ　ＭＥＤＩＣＩＮＥ Ｖ３２８　Ｎ３, 1993, Ｐ２０５-２０６ *
JPN5007021136; ＬＡＶＯＲＡＴＴＩ　Ｇ　Ｃ: ＮＥＰＨＲＯＬＯＧＹ　ＤＩＡＬＹＳＩＳ　ＴＲＡＮＳＰＬＡＮＴＡＴＩＯＮ Ｖ９　Ｎ１１, 1994, Ｐ１６４５-１６４８ *
JPN5007021137; ＧＯＣＨ　Ｊ: ＥＵＲＯＰＥＡＮ　ＪＯＵＲＮＡＬ　ＯＦ　ＨＡＥＭＡＴＯＬＯＧＹ Ｖ５５　Ｎ２, 199508, Ｐ７３-７７ *
JPN5007021139; ＹＡＱＯＯＢ　Ｍ: ＰＯＳＴＧＲＡＤＵＡＴＥ　ＭＥＤＩＣＡＬ　ＪＯＵＲＮＡＬ Ｖ６９　Ｎ８０８, 199302, Ｐ１２４-１２８ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010032489A1 (ja) 2008-09-22 2010-03-25 国立大学法人旭川医科大学 鉄キレート剤及びその製造方法、並びに鉄イオンの定量・捕捉方法
US8623661B2 (en) 2008-09-22 2014-01-07 National University Corporation Asahikawa Medical College Iron chelating agent, method for producing same, method for determining amount of iron ions and method for trapping iron ions
WO2012096183A1 (ja) 2011-01-14 2012-07-19 株式会社ダステック 高分子鉄キレート剤
US9796605B2 (en) 2011-01-14 2017-10-24 Disease Adsorption System Technologies Co., Ltd. Polymeric iron chelating agent

Also Published As

Publication number Publication date
EP1819334A1 (en) 2007-08-22
CA2587558A1 (en) 2006-05-26
AU2005306772A1 (en) 2006-05-26
WO2006055412A1 (en) 2006-05-26
US20060128805A1 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
JP2008520669A (ja) エリスロポエチン抵抗性を治療する方法
Kamper et al. Effect of enalapril on the progression of chronic renal failure: a randomized controlled trial
Nesrallah et al. Volume control and blood pressure management in patients undergoing quotidian hemodialysis
Kaupke et al. Effect of erythrocyte mass on arterial blood pressure in dialysis patients receiving maintenance erythropoietin therapy.
JP5592609B2 (ja) 鉄代謝改善剤
Van der Zee et al. Vasopressin administration facilitates fluid removal during hemodialysis
Hayes et al. Successful reduction of plasma free-hemoglobin using therapeutic plasma exchange: a case report
Bianchi et al. Long-term effects of enalapril and nicardipine on urinary albumin excretion in patients with chronic renal insufficiency: a 1-year follow-up
Bradley et al. Hematopoietic effect of Radix angelicae sinensis in a hemodialysis patient
JP2009501739A (ja) 腎臓障害の予防または処置のための可溶性グアニル酸シクラーゼの活性化剤および刺激剤の新規使用
US7235542B2 (en) Diagnosis and treatment of human kidney diseases
Panesar et al. Safety and efficacy of sodium ferric gluconate complex in patients with chronic kidney disease
Thabet et al. Vitamin E in renal therapeutic regimens
Eiselt et al. The effect of intravenous iron on oxidative stress in hemodialysis patients at various levels of vitamin C
CN108135886A (zh) 用于糖尿病性肾病治疗的pde4抑制剂
JP5564159B2 (ja) 血液透析から生じる酸化ストレスおよび急性または慢性腎疾患の予防および治療を目的としたシスチンまたはシステインの使用
AU2014264537B2 (en) Dialysis formulation
Wight et al. Short-term effects of calcium antagonists on renal haemodynamics in patients with chronic renal failure
Bellomo et al. Recent trials in critical care nephrology
Kanegae et al. Pharmacokinetics of bisoprolol and its effect on dialysis refractory hypertension
AU4653400A (en) Diagnosis of human kidney diseases
Taccone-Galluci et al. Oxidative damage to RBC membranes and pentose phosphate shunt activity in hemodialysis patients after suspension of erythropoietin treatment
Rasmussen et al. Postpartum renal failure and malignant hypertension treated with captopril
Aoun Patients with end-stage kidney disease undergoing hemodialysis: considerations for the dental practitioner
Ito et al. MO525: Iron absorption and phosphate-lowering effects of ferric citrate hydrate are not influenced by gastric secretion inhibitors in patients with chronic kidney disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120302

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120309

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121012